Multiple Programs With Significant Value Creation

PROGRAM
THERAPEUTIC AREA
STAGE / STATUS
VALUE INFLECTION
ICOTYDE™ Oral IL-23R
I&I
Approved for Mod to Sev Plaque PsO
Launch trajectory
Ph2 and Ph3 readouts
MIMRYLO™ Hepcidin mimetic
Hematology
Approved for Erythrocytosis in PV
Launch trajectory
PN-881 Oral IL-17A/F
I&I
Ph1; Ph2b Mod to Severe Plaque PsO
Ph1 safety/PK completion
Ph2b PsO dose finding/PoC
PN-477 Triple agonist; oral + SC
Metabolic
Ph1 SC and Oral
Ph1 SC SAD/Ph1b MAD (13 weeks) PoC
Ph1 Oral SAD/MAD (7-day)
Ph1b Oral MAD (13 weeks) PoC
PN-458 Dual agonist; oral
Metabolic
Ph1 start planned
Ph1 Oral SAD/MAD
PN-8047 Oral hepcidin
Hematology
Ph1 start planned
Ph1 SAD/MAD PD PoC
Ph2 PV study
Discovery IL-4Rα; amylin
Discovery
Candidate selection
Multiple development candidates

IL, interleukin; MAD, multiple ascending dose; PD, pharmacodynamics; PK, pharmacokinetics; PoC, proof of concept; PsO, psoriasis; PV, polycythemia vera; SAD, single ascending dose; SC, subcutaneous.